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Abstract
While humans and most animals respond to µ-opioid receptor (MOR) agonists with analgesia and decreased
aggression, in the naked mole rat (NMR) opioids induce hyperalgesia and severe aggression. Single nucleotide
polymorphisms in the human mu-opioid receptor gene (OPRM1) can underlie altered behavioral responses to
opioids. Therefore, we hypothesized that the primary structure of the NMR MOR may differ from other species.
Sequencing of the NMR oprm1 revealed strong homology to other mammals, but exposed three unique amino acids
that might affect receptor-ligand interactions. The NMR and rat oprm1 sequences were cloned into mammalian
expression vectors and transfected into HEK293 cells. Radioligand binding and 3'-5'-cyclic adenosine
monophosphate (cAMP) enzyme immunoassays were used to compare opioid binding and opioid-mediated cAMP
inhibition. At normalized opioid receptor protein levels we detected significantly lower [3H]DAMGO binding to NMR
compared to rat MOR, but no significant difference in DAMGO-induced cAMP inhibition. Strong DAMGO-induced
MOR internalization was detectable using radioligand binding and confocal imaging in HEK293 cells expressing rat or
NMR receptor, while morphine showed weak or no effects. In summary, we found minor functional differences
between rat and NMR MOR suggesting that other differences e.g. in anatomical distribution of MOR underlie the
NMR's extreme reaction to opioids.
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Introduction
The µ-opioid receptor (MOR) mediates the analgesic
properties of MOR ligands (e.g. morphine), the oldest and most
powerful analgesics [1]. OPRM1-like sequences have been
present since the beginning of vertebrate evolution and remain
highly homologous across a broad range of species [2].
Accordingly, the behavioral response to MOR agonists is also
highly conserved and includes analgesia, sedation, and
decreased aggression [3]. However, one exception is the
naked-mole rat (NMR) which displays hyperactivity, motor
dysfunction and, most notably, extreme aggression in response
to MOR agonists [4,5]. These behaviors are reversible by
naloxone (NLX), a non-selective opioid receptor antagonist,
demonstrating that these effects are mediated by opioid
receptor activation. Furthermore, morphine induced
hyperalgesia in the hot-plate test (4) and much higher doses of
opioids were required to produce analgesia in the formalin test
compared to mice (5). The molecular basis for these unique
reactions has not been examined so far.
Studies have described dramatic effects of single nucleotide
polymorphisms (SNPs) in the 5’-end of OPRM1. The most
prominent is the N40D mutation (A118G), which is naturally
occurring in up to 50% of humans and is associated with
increased consumption of analgesics [6–9]. Multiple studies
have described a similar SNP in rhesus macaque and in a
mouse model of the human SNP, both of which mimic the
behavioral alterations to opioids occurring in humans carrying
this SNP [10,11]. Interestingly, these SNPs are also associated
with heightened aggression, stronger maternal bonding, and
increased social attachment [12–15], and several in-vivo
[16,17] and in-vitro [18–20] studies examining the effects of
OPRM1 SNPs show significant changes in ligand binding and
receptor activation
Because of the behavioral alterations associated with SNPs
in the MOR gene, we hypothesized that the reactions to opioids
observed in the NMR might be associated with amino acid (aa)
alterations in MOR. Therefore, we sequenced the oprm1 of the
NMR in order to compare its primary structure to those of other
species. To test the hypothesis that a unique aa alteration in
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the NMR MOR alters its function, we cloned the receptor into a
bicistronic mammalian expression vector for analysis of
radioligand binding, receptor endocytosis and MOR-mediated
3’-5’-cyclic adenosine monophosphate (cAMP) repression.
Materials and Methods
Agreed ethics statement
Tissue used to isolate RNA or DNA was obtained from
animals that died of natural causes. All tissue used in the study
was obtained from animals housed in two breeding colonies at
the Leibniz Institute for Zoo and Wildlife Research, Berlin,
Germany and was donated by Dr. Thomas Hildebrandt.
Primer synthesis
Primers were designed based on rat, mouse and guinea pig
oprm1 sequences published on PubMed nucleotide (Accession
numbers NM_O13071, U26915, and NM_001172738,
respectively). A homology map of these oprm1 sequences
using the program PRALINE (Amsterdam, the Netherlands)
was created and areas with the most highly conserved regions
were used to design primers. Since the NMR’s closest relative
with a published oprm1 sequence is the guinea pig, we based
our final primers on the guinea pig oprm1 sequence. Primers
ranging from 12 to 26 base pairs were synthesized by TIB
MOLBIOL Syntheselabor GmbH (Berlin, Germany). Over 30
different primers were tested and those with the closest match
to the NMR sequence are listed in Table S1.
Polymerase chain reaction (PCR) and sequencing
PCR reactions were prepared with Thermo Scientific
Phusion® DNA polymerase according to the manufacturer's
instructions and at the following temperatures: After
denaturation at 98°C for 30 s, 40 cycles with denaturation at
98°C for 10 s, primer annealing at 55 °C for 45 s, and
elongation at 72°C for 45 s were performed. PCR products
were run on a 1% agarose gel and single bands of interest
were isolated using the Qiagen Extraction Kit. Purified products
were sent for sequencing to AGOWA Genomics (Berlin,
Germany). For sequence alignments and homology searches
we utilized the www.ncbi.nlm.nih.gov database and A Plasmid
Editor software. We published the entire coding sequence of
the NMR oprm1 online in the National Center for Biotechnology
Information (Accession number JQ011280).
2D Protein prediction and sequence alignment
The online program TMRPres2D [21] was used to predict the
number of transmembrane domains in the NMR MOR and to
create a 2D model (Figure 1A). The complete aa sequence of
the NMR MOR was aligned with the MOR of 9 other species
published on the NCBI website using the online tool PRALINE
(http://www.ibi.vu.nl/programs/pralinewww, University of
Amsterdam, The Netherlands, Figure 1 B). Accession numbers
were: AEX59148 (NMR), NP_001166209 (Cavia porcellus),
NP_001029087 (Pan troglodytes), XP_003432592 (Canis
lupus familiaris), AAB49477 (Bos Taurus), AAF97249 (Macaca
mulatta), AAH74927 (Homo sapiens), AAB53770 (Sus scrofa),
AAI19546 (Mus musculus), NP_037203 (Rattus norvegicus)
Cloning and mutagenesis
To create oprm1-containing vectors for transfection, we
extended single restriction sites at the 5' and 3' ends of
amplified oprm1 and inserted the resulting amplicons into the
pIRES2-eGFP (enhanced green fluorescent protein) vector
directly downstream of the CMV-promoter. The transfection
primers and restriction enzymes are listed in Table S2; vector
maps for rat and NMR pCMV-oprm1-IRES-eGFP are provided
in Text S1 and S2, respectively. For imaging of cellular
localization, the IRES sequence separating oprm1 from eGFP
was removed using the QuickChange® site-directed
mutagenesis kit (Agilent Technologies, California, USA) to
create viable eGFP fusion proteins. Although the mutagenesis
kit is mainly applied to replace one or few nucleotides, it can
also be used to insert or excise larger sequences, as described
by the manufacturer. Chimeric oligonucleotide primers were
designed that were complementary to 4-5 codons of the oprm1
3’-end before the stop and of the eGFP 5’-end including the
start site; primer sequences are given in Table S3. Extension of
the oligonucleotide primers generated mutated plasmids
without oprm1 stop and IRES, but containing staggered nicks.
Following amplification, the product was treated with Dpn I to
remove the parental DNA template. The mutated vector DNA
was then transfected into competent cells for nick repair.
Colonies were tested for the absence of IRES using PCR, and
NMR pCMV-oprm1-eGFP vector DNA (see Text S3 for vector
map) was used for transfection and confocal imaging.
Cell culture and transfection
HEK293 cells (DSMZ, Braunschweig, Germany) were
cultured in Dulbeccos’s Modified Eagle’s Medium with 10%
fetal bovine serum and 1% penicillin at 37°C with 5% CO2. One
day prior to transfection roughly 2 x 106 cells were seeded on
10 cm diameter (78.5 cm2) culture dishes. Cells were
transiently transfected using FuGENE HD and EXTREME
transfection reagent (Roche Applied Science) according to the
manufacturer’s protocol, and at a ratio of 2:1 FuGENE to DNA.
Cells were harvested for membrane preparations 24 h post
transfection. Two dishes transfected with the same vector DNA
were pooled for saturation binding experiments. For whole cell
binding experiments approximately 0.6 x 106 cells were grown
and transfected in 25 cm2 cell culture bottles. Six bottles were
transfected with the same transfection mixture in each
experiment. For imaging, cells were grown on polylysine-
coated glass in 6-well plates; nine wells were transfected with
the same transfection mixture.
Membrane preparations
Rat/NMR pCMV-oprm1-IRES-eGFP transfected HEK293
cells were washed twice with ice cold assay buffer (50 mM
Tris-HCl, 1 mM EGTA, pH 7.4). Cells were then scraped from
the culture dish in 10 ml ice cold assay buffer, homogenized
with a Polytron homogenizer (Kinematica AG, Littau,
Switzerland), and centrifuged at 42,000 g at 4°C for 20 min.
Pellets were resuspended in assay buffer and homogenization
Naked Mole Rat µ-Opioid Receptor
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was repeated twice. Subsequent to protein measurement the
membranes were aliquoted and stored at -80°C.
Cell lysates were processed using a plasma membrane
protein extraction kit (Abcam) following the manufacturers'
instructions. Cells were lysed by repeated freezing (liquid
nitrogen) and thawing (37°C water bath) in homogenization
buffer supplemented with protease inhibitors. Debris was
removed by centrifugation (700 g for 10 min at 4°C). Total
membrane protein was isolated from the cytosol fraction by
high speed centrifugation of the supernatants (10,000 g for 30
min at 4°C). Pellets containing proteins from both plasma
membrane and cellular organelle membranes were then
resuspended in upper phase solution, mixed with lower phase
solution, and centrifuged at 1,000 g for 5 min. The upper phase
was collected and mixed for extraction with lower phase
solution. After centrifugation (1,000 g for 5 min) the supernatant
was harvested and diluted in water. Pellets obtained after a
final centrifugation at top speed in a microcentrifuge (10 min,
4°C) were used for radioligand binding.
Radioligand saturation binding assay
Tritium-tagged DAMGO ([D-Ala2, N-MePhe4, Gly-ol]-
enkephalin, Perkin Elmer) was used as previously described
[22]. Total binding was determined using approximately 100 µg
of membrane protein for each concentration of [3H]DAMGO (1,
2, 4, 8, 16 and 32 nM). Non-specific binding was determined at
each concentration of [3H]DAMGO by using 10 µM NLX. All
measurements were performed in duplicate. Specific binding
was calculated as the difference between the counts per
minute (CPM) of total and non-specific binding. In addition,
binding to non-transfected HEK293 cells was determined. This
showed no differences between total and non-specific binding.
The specific CPM were divided by the specific activity of
[3H]DAMGO (81.7 CPM/fmol) to calculate the amount of bound
ligand at each concentration in fmol/mg of total protein. A non-
linear regression one-site binding model provided by GraphPad
Prism was fit to each construct measured in each experiment in
order to calculate the asymptote (Bmax) or maximum amount
of bound ligand in fmol. The amount of MOR in each
Figure 1.  The NMR MOR N-terminus contains unique amino acids (aa) compared to other species.  A) 2-D prediction of the
NMR MOR secondary structure. B) The first 70 aa of the N-terminus of the NMR MOR are compared to 9 different mammalian
species. Amino acid variations unique to the NMR compared to the other species are marked with asterisks.
doi: 10.1371/journal.pone.0079121.g001
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transfection was then calculated from the Bmax. Assuming that
one molecule of ligand binds to one molecule of MOR, and a
Hill slope of 1, the total amount of receptor per sample was
calculated in μg. The molecular mass of each receptor was
predicted based on its aa sequence (NIH Acession numbers
NP_037203 for the rat MOR and AEX59148 for the NMR MOR)
using the online Protein Mass Calculator (University of Leeds,
United Kingdom). The molecular mass was 44.5 kDa for the rat
and 44.8 kDa for the NMR MOR. Binding data were normalized
by dividing the specific CPM values at each ligand
concentration by the amount of MOR (in μg) in that sample.
Using GraphPad Prism 4.0c, these normalized values were
plotted and fit with a non-linear regression one-site binding
model to determine Kd values. The mean area under the curve
(AUC) for each construct was calculated.
Radioligand binding to plasma membrane
To determine if the MORs expressed in transfected HEK293
cells were inserted into the cell membrane, plasma membrane
extracts were subjected to [3H]DAMGO binding. Only one
concentration (16 nM) of radioligand was tested. Non-specific
binding was determined by the addition of 10 µM NLX.
Whole cell radioligand binding
Whole cell [3H]DAMGO binding was performed to determine
receptor internalization according to Evans’ protocol [23].
Rat/NMR pCMV-oprm1-IRES-eGFP transfected HEK293 cells
were exposed for 30 min at 37°C to 10 µM untagged DAMGO
(Sigma-Aldrich), 10 µM morphine-sulfate (Sigma-Aldrich) or to
vehicle (HBSS buffer supplemented with NaHCO3). Another set
of cells was pre-incubated with 0.4 M sucrose in HBSS buffer
for 30 min at 37°C prior to agonist exposure to inhibit opioid
receptor internalization as previously described [24]. Cells were
washed twice with ice cold HBSS and incubated for 5 min at
4°C in low pH stripping buffer (0.2 M acetic acid, 0.5 M saline,
pH 2.5) to remove surface-bound but not internalized ligands
that could interfere with radioligand binding. Subsequent to two
washing steps, the cells were harvested and resuspended in
cold HBSS buffer (1.6 ml per cell culture bottle). 0.4 ml of the
suspensions were exposed to 16 nM [3H]DAMGO (total
binding) or 16 nM [3H]DAMGO plus 10 µM NLX (non-specific
binding) in duplicates. This incubation was performed for 2 h at
4°C to promote binding of the radioligand to surface receptors
and to prevent further receptor internalization. Cells were then
transferred to 0.1% polyethyleneimine-presoaked GF/B filters
(Whatman), unbound radioligand was removed by washing
with 50 mM Tris buffer, and filters were incubated for 24 h in 3
ml scintillation liquid. Specific CPM were calculated by
subtracting non-specific from total counts determined in a beta
counter and reflected binding to MOR expressed on the cell
surface. Specific counts were compared between sucrose pre-
treated (maximum binding) and untreated cells using the paired
t-test. Lower CPM in the untreated cells was interpreted as
receptor internalization. Using GraphPad Prism 4.0c, values
were then plotted as percentages of maximum binding.
3'-5'-cyclic adenosine monophosphate enzyme-
immunoassay (cAMP EIA)
Opioid-induced inhibition of cAMP formation was assessed
using the cAMP Biotrak Enzymeimmunoassay (GE
Healthcare). HEK293 cells were seeded in 96-well plates and
transfected with rat/NMR pCMV-oprm1-IRES-eGFP vectors for
18-36 h prior to the assay. Cells were washed twice with PBS
and incubated for 20 min with 100 µl extracellular solution
(ECS: 2 mM CaCl2, 10 mM Glucose, 10 mM HEPES, 5 mM
KCl, 2 mM MgCl2, 140 mM NaCl, adjusted to pH 7.5 with
NaOH) containing either 1) no drug, 2) the cAMP activator
forskolin (10 µM) + the phosphodiesterase inhibitor IBMX (2
µM) (FI), 3) FI + the MOR agonist DAMGO (10 µM), or 4) FI +
DAMGO + NLX (20 µM). The ECS was then removed and cells
were lysed for 10 min at room temperature with 200 µl lysis
reagent. Next, 100 µl of lysate was transferred to an antigen-
coated (donkey anti-rabbit IgG) EIA plate. All samples were
arranged in duplicates. cAMP levels were detected with a
microplate reader at 450 nm using SOFTmax® Pro software.
All cAMP values were normalized to total amount of protein
measured in each sample immediately following lysis using the
Bradford method. Values were statistically analyzed using the
Friedman test followed by Dunn's Multiple Comparison Test to
compare the effect of DAMGO or DAMGO plus NLX on the
formation of cAMP following forskolin treatment for each vector.
To compare the effects between the rat and NMR MOR, data
were transformed into % of forskolin-induced cAMP levels and
analyzed using Kruskal-Wallis test followed by Dunn's Multiple
Comparison Test.
Imaging of cellular MOR localization
HEK293 were plated on 1.2 cm polylysine-coated glass
slides and transiently transfected with either WT rat or NMR
pCMV-oprm1-eGFP vector DNA one day prior to imaging. Cells
were washed three times in PBS and incubated with either
PBS, 10 µM DAMGO in PBS, or 10 µM morphine-sulfate in
PBS for 20-30 min at 37°C. Cells were then washed again in
PBS and fixed for 15 min in 4 % PFA and 4% sucrose. After
blocking (30 min in PBS containing 5% normal goat serum and
0.3% Triton™ X-100) slides were incubated overnight at 4°C
with polyclonal rabbit anti-EEA1 (early endosomal marker 1)
(Cell Signaling Technologies, 1:1000 in PBS containing 1%
BSA and 0.3% Triton™ X-100). Slides were washed three
times using PBS and incubated for 1 h at room temperature
with the secondary antibody (Alexa Fluor® 568 Goat Anti-
Rabbit IgG, Life Technologies, 1:200 in PBS containing 1%
BSA and 0.3% Triton™ X-100). After washing in PBS, the
glass slides were mounted on microscope slides with Mowiol®
4-88. Slides were dried overnight and viewed under a Zeiss
LSM 510 Meta confocal laser scanning microscope.
Fluorescence images were obtained using excitation
wavelengths of 543 nm and 488 nm (63 x oil-immersion
objective). Z-stacks were performed on 3.8-4.1 x zoomed
regions usually showing 2-6 transfected cells. Every 0.38 µM a
picture was taken and the pinhole size was set to 0.7 µM. Co-
localization of EEA1 and eGFP was analyzed in vesicular
structures using ImageJ 1.46r (Wayne Rasband, National
Institutes of Health) software and the ImageJ plugin Organelle
Naked Mole Rat µ-Opioid Receptor
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Based Colocalisation (OBCOL) 1.45 (Nick Hamilton, Ben
Woodcroft, Luke Hammond, and Jenny Stow, Institute for
Molecular Bioscience, The University of Queensland,
Queensland, Australia). All unwanted content (e.g. non-
transfected cells, improper stack slices) was removed from the
stacks, and then the channels were split. A lower intensity
threshold was set for each channel (usually 35 for eGFP and
65 for EEA1). The two converted single channel stacks were
then added to OBCOL. After processing the co-localization and
object, statistics for each individual object was performed
setting the minimal pixel filter to 250-10,000 pixels. The
Manders’ coefficients representing the % overlap of eGFP and
EEA1 (M1) of individual objects are given.
Results and Discussion
Sequencing and analysis of the NMR oprm1
We first sequenced and analyzed the complete CDS of the
NMR oprm1. Primers were designed based on the most
broadly conserved regions of the mammalian oprm1 (Table
S1). Segments ranging from 250-700 base pairs were
produced using PCR amplification of NMR gDNA and cDNA
and assembled into a single sequence by aligning overlapping
regions. The CDS is 1,203 nucleotides long and codes for a
400 aa long 7-transmembrane G-protein coupled receptor
(GPCR) highly similar (greater than 90% nucleotide match) to
oprm1 variants comprising exons 1, 2, 3 and 4 of a range of
species including humans, rats and mice (Figure 1A). While
conducting the experiments, Kim et al. sequenced the whole
NMR genome. Our NMR oprm1 CDS had a nearly 100% match
to the 4 sequential exons published [25]. Moreover, recent
transcriptome sequencing of the NMR by Szafranski and
colleagues revealed a perfect match with our NMR oprm1 CDS
[26]. Three nucleotide substitution sites were identified in highly
conserved regions of the 5’-end of the oprm1 resulting in three
unique aa at the N-terminal NMR MOR compared to all other
species examined (Figure 1B).
[H3]DAMGO binding is stronger in WT rat compared to
NMR MOR
Upon completion of the NMR and rat pCMV-oprm1-IRES-
eGFP vectors, we checked their ability to bind opioid ligands.
Plasma membrane extracts of transiently transfected HEK293
cells were analyzed using radioligand binding assays with the
tritium-tagged MOR-selective agonist DAMGO. Both receptors
bound [3H]DAMGO showing that MOR was expressed and
integrated into the cell membrane (Figure 2A). No significant
difference between rat and NMR MOR was detected in CPM
values (two-tailed Mann Whitney U test, p > 0.05). To account
for variations in the amount of transiently expressed receptor,
the amount of bound ligand per fmol of MOR was determined
in saturation binding assays. Data nomalized to the amount of
MOR expressed were then calculated as area under the curve
(AUC) of the non-linear regression fit according to one-site
binding. In membrane preparations of transiently transfected
HEK293 cells, the NMR MOR bound significantly lower
amounts of [H3]DAMGO (AUC: 55,631 ± 1,675) compared to
the rat MOR (AUC: 60,218 ± 482.3; two-tailed Mann Whitney U
test, p < 0.05), indicating that the NMR receptor bound
[H3]DAMGO with less affinity compared to WT rat MOR (Figure
2B). Consistently, the dissociation constant (Kd) of
[H3]DAMGO and MOR was significantly higher for the NMR
(2.42 ± 0.48 nM) as compared to the rat (1.45 ± 0.11 nM) (two-
tailed Mann Whitney U test, p < 0.05). These results may
provide a molecular explanation for the finding that NMR
require higher doses of opioids to induce analgesia in vivo
[27,28]. Our data resemble an in vitro saturation binding study
showing lower binding of DAMGO to the human MOR variant
D40 as compared to the WT N40 [19]. Consistently, a reduced
in vivo MOR receptor binding potential of D40 was described
[16,17] and patients homozygous for D40 showed increased
post-operative morphine demands [6–9]. There is some
evidence that the reduced surface expression of D40 is the
consequence of the loss of one out of five glycosylation sites in
the human MOR [19,29]. Due to a glycine instead of serine at
aa 11, the NMR MOR contains only three putative glycosylation
sites but the receptor density and expression level in NMR
tissues is unknown so far.
Figure 2.  Radioligand binding of rat and NMR MOR.  A)
[H3]DAMGO binding to plasma membrane extracts of rat and
NMR MOR expressed in HEK293 cells (pCMV-oprm1-IRES-
eGFP vector DNAs). Data are shown as whisker blots (min to
max). B) Normalized [H3]DAMGO saturation binding curve of
rat and NMR MOR expressed in HEK293 cells (pCMV-oprm1-
IRES-eGFP vector DNAs) using whole membrane
preparations. Data represent means ± SEM. Statistical analysis
was performed using the two-tailed Mann Whitney U test.
doi: 10.1371/journal.pone.0079121.g002
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MOR-mediated cAMP inhibition is similar in rat and
NMR
Next we examined differences in downstream signaling. In
general, opioid binding activates inhibitory Gα subunits, thereby
reducing adenylyl cyclase activity which decreases cAMP
formation [30]. Forskolin-induced cAMP formation was
significantly reduced following DAMGO application in both rat
(161 ± 59 fmol/1 µg protein in FI versus 100 ± 32 fmol/1 µg
protein in FI + DAMGO, Friedman test and Dunn's Multiple
Comparison Test, p < 0.05) and NMR MOR (213 ± 54 fmol/1
µg protein in FI versus 136 ± 40 fmol/1 µg protein in FI +
DAMGO, Friedman test and Dunn's Multiple Comparison Test,
p < 0.05) (see also Figure 3). This inhibition of forskolin-
induced cAMP formation was not significantly different between
the NMR (-42 ± 11%) and rat MOR (-33 ± 7%) (Mann Whitney
U test, p > 0.05) and naloxone reduced the DAMGO effect
(Figure 3), in accordance with other findings [31]. Previous in
vitro analysis of MOR mutants revealed no significant changes
in morphine-induced cAMP inhibition at high (1 µM) [18] but
demonstrated differences at low (1-100 nM) agonist
concentrations [19]. It is possible that no differences in cAMP
inhibition were detected in the present study due to the high
dose of DAMGO used (10 µM).
Figure 3.  cAMP inhibition by rat and NMR MOR
activation.  Intracellular cAMP levels were measured using
EIA in HEK293 cells transfected with NMR (n = 4) and rat (n =
6) pCMV-oprm1-IRES-eGFP vector DNAs following treatment
with forskolin/IBMX (FI; 10 µM/2 µM) and either DAMGO (10
µM) or DAMGO and NLX (20 µM). Data are presented as the
percentage of FI-stimulated cAMP formation (means ± SEM).
Statistical analysis was performed on raw data (fmol) after
normalization to protein. Friedman test and Dunn's Multiple
Comparison Test, * p < 0.05 compared to FI-stimulated cAMP
formation.
doi: 10.1371/journal.pone.0079121.g003
Rat and NMR MOR show similar trafficking in response
to DAMGO and morphine
Finally we determined agonist-induced MOR trafficking by
whole cell radioligand binding of the rat and NMR MOR. In
agreement with previous literature [32,33], DAMGO (but not
morphine or vehicle) markedly reduced surface-bound
radioligand without sucrose pretreatment in rat MOR,
suggesting endocytosis (paired t-test, p < 0.01, Figure 4A).
While no significant CPM effect of sucrose pretreatment was
found in vehicle-treated cells (paired t-test, p > 0.05, Figure
4A), some internalization was observed in three out of six
experiments. This may reflect constitutive receptor recycling.
Also, the NMR MOR showed reduced surface binding in
response to DAMGO (paired t-test, p < 0.001, Figure 4B) but
not to morphine or vehicle (paired t-test, p > 0.05, Figure 4B).
The percentage of sucrose-blocked endocytosis did not differ
between the WT rat and NMR MOR (unpaired t-test, p > 0.05),
suggesting similar receptor trafficking in the two species.
To confirm these findings we used confocal microscopy of
cells transfected with pCMV-NMRoprm1-eGFP. Opioid
receptor fusions with eGFP have previously been shown to
have no effect on receptor binding, signaling, or trafficking
when expressed in HEK293 cells [34,35]. Plasma membrane
extracts of transiently transfected HEK293 cells expressing
eGFP-tagged MOR were analyzed using radioligand binding to
verify surface expression. The receptor was expressed and
integrated into the cell membrane (Figure S1A). Cells were
stained for EEA1 to differentiate between eGFP-positive
vesicular structures trafficking towards the cell membrane and
eGFP-positive endosomes. The NMR MOReGFP showed a
reasonable increase in the number of vesicular objects with
high eGFP/EEA1 co-expression in DAMGO-treated cells in
comparison to untreated control cells, while only few of such
double-positive objects were observed in morphine-treated
cells. Sequencing of the plasmid verified that pCMV-
NMRoprm1eGFP was intact. These findings indicate
internalization of the NMR MOReGFP predominantly after
DAMGO and to a lesser degree after morphine stimulation,
which is similar to the findings of others [33,36,37] and
supports our data obtained in the whole cell ligand binding
assay.
Conclusions
Comparison of the NMR MOR sequence to other mammals
revealed high overall homology but also highlighted some
unique aa. We found differences in DAMGO binding between
the NMR and rat MOR, while cAMP inhibition was similar. In
addition, both receptors internalized strongly after DAMGO but
less so after morphine stimulation. Taken together, we
conclude that the NMR MOR is functionally indifferent from the
rat receptor.
How do these findings compare to the unusual NMR
behavior in response to morphine? Reduced stepping latencies
after opioid application in the hot-plate test [4,38,39] may have
been due to the known hyperlocomotion induced by high doses
of morphine [40,41] since opioids demonstrated normal
analgesic action in the NMR in another pain test (formalin-
Naked Mole Rat µ-Opioid Receptor
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induced pain) [5,27,28]. Together with the data presented here
we suggest that the NMR MOR displays normal functionality in
terms of locomotion and pain inhibition.
A remaining question is how MOR agonists induce
aggression in the NMR. In animals treated with ≥ 10 mg/kg
morphine or ≥ 20 mg/kg pethidine aggression was so strong
that all animal housed together died due to vigorous fighting
[4,38]. The present study did not provide an explanation of
these findings. To address this issue examination of MOR
density and localization in the NMR nervous system may be
Figure 4.  Surface expression of rat and NMR MOR
following agonist stimulation.  HEK293 cells transiently
transfected with either A) rat or B) NMR pCMV-oprm1-IRES-
eGFP vector DNA were incubated with either HBSS buffer
(control), 10 µM DAMGO, or 10 µM morphine for 30 min at
37°C. To block internalization, cells were pre-treated with
sucrose. Removal of bound but not internalized ligand was
performed in low pH stripping buffer before cells were exposed
to [3H]DAMGO. Six independent experiments were performed.
Data represent surface-bound CPM in % of sucrose pre-treated
cells (means ± SEM). Statistical analysis was performed using
the paired t-test, * p < 0.05 and ** p < 0.01.
doi: 10.1371/journal.pone.0079121.g004
necessary. In this context, an altered connectivity of TRPV1
channels was found to be responsible for the NMR’s behavioral
insensitivity to capsaicin [42] and polymorphism-dependent
differential localization and density of the A112 and G112
SNPs of the mouse MOR were observed throughout the mouse
brain [43]. The NMR’s extreme reaction to opioids surely
makes it difficult to investigate opioid analgesia but studying
the relationship between the anatomical localization of opioid
receptors and the behavioral outcomes may promise new
insights.
Supporting Information
Figure S1.  Internalization of NMR MOR-eGFP following
agonist stimulation. HEK293 cells were transiently
transfected with NMR pCMV-oprm1eGFP vector DNA to
express MOR with a C-terminal eGFP tag for confocal analysis.
A) Surface expression of NMR MOReGFP fusion protein was
analyzed using radioligand binding to plasma membrane
extracts. Data are shown as whisker blots (min to max, n = 5).
B) Cells were incubated with either PBS (control), 10 µM
DAMGO, or 10 µM morphine. PFA-fixed cells were then
stained for EEA1, mounted in Mowiol and imaged with a Zeiss
LSM 510 Meta confocal laser scanning microscope. Z-stacks
were analyzed as detailed in the methods. Data represent
Manders’ coefficients (M1, overlap of MOReGFP to EEA1; 1 =
100% co-localization, 0 = no co-localization) determined in
vesicular objects across 2-3 stacks per slide. Three slides were
analyzed per treatment.
(TIF)
Table S1.  Primers used to sequence the NMR oprm1.
(DOC)
Table S2.  Transfection primers used to clone the complete
CDS of NMR and rat oprm1 into empty pIRES2-eGFP
vector.
(DOC)
Table S3.  Mutagenesis primer used to excise IRES from
NMR pCMV-oprm1-IRES-eGFP.
(DOC)
Text S1.  Rat pCMV-oprm1-IRES-eGFP Vector map.
(PDF)
Text S2.  NMR pCMV-oprm1-IRES-eGFP Vector map.
(PDF)
Text S3.  NMR pCMV-oprm1eGFP Vector map.
(PDF)
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